Of the 32 RA patients, five were in treatment with TNF inhibitors (Adalimumab®, Certolizumab® or Etanercept®), four with the IL-6 receptor antagonist Tocilizumab® and three with T-cell activation inhibitor Abatacept®. Here, TNF is linked to rheumatoid arthritis.